Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 2/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20121591 | 0.93 | KCNH2 (0.60) | KCNH2POLBMLNRCSNK1DCSNK1E | |
| SCHEMBL20121604 | 0.91 | KCNH2 (0.59) | KCNH2POLBMLNRCSNK1DCSNK1E | |
| SCHEMBL12952023 | 0.89 | KCNH2 (0.69) | KCNH2POLBMLNRCYP3A4MCHR1 | |
| SCHEMBL997790 | 0.86 | KCNH2 (0.62) | KCNH2CSNK1DCSNK1ECYP3A4 | |
| SCHEMBL20121541 | 0.85 | KCNH2 (0.57) | KCNH2POLBMLNRCSNK1EMAPT | |
| SCHEMBL20121610 | 0.84 | KCNH2 (0.70) | KCNH2MLNRCYP3A4MCHR1 | |
| SCHEMBL12952035 | 0.84 | KCNH2 (0.66) | KCNH2CSNK1DCSNK1ECYP3A4MAPT | |
| SCHEMBL12952031 | 0.84 | KCNH2 (0.68) | KCNH2POLBMLNRCYP3A4MAPT | |
| SCHEMBL12951892 | 0.83 | KCNH2 (0.56) | KCNH2CSNK1DCSNK1ECYP3A4MAPT | |
| SCHEMBL20121567 | 0.82 | KCNH2 (0.63) | KCNH2CSNK1DCSNK1ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |